(Total Views: 718)
Posted On: 04/01/2021 8:54:27 PM
Post# of 156272
Re: melsdollars #85032
Half life issue could completely explain the CD12 results.
62 critical patient group sees 82% mortality benefit.
If a severe patient is dosed at days 0 and 7 and does not progress to critical until day 21, then the severe patient did not have leronlimab in his blood when he needed it.
This explanation is also congruent with improvements in care during CD12 that extended the lifetime of hospitalized patients.
Dose a severe at day 0 and day 7, if good hospital care delays the progression to critical until day 14, then the severe does not have leronlimab when he needs it.
62 critical patient group sees 82% mortality benefit.
If a severe patient is dosed at days 0 and 7 and does not progress to critical until day 21, then the severe patient did not have leronlimab in his blood when he needed it.
This explanation is also congruent with improvements in care during CD12 that extended the lifetime of hospitalized patients.
Dose a severe at day 0 and day 7, if good hospital care delays the progression to critical until day 14, then the severe does not have leronlimab when he needs it.
(9)
(0)
